Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
Company Details
- Employees
- 23
- Address
- 733 Industrial Rd, San Carlos,california 94070,united States
- Phone
- (415)617-5755
- in****@****ine.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- glycomine.com
- HQ
- San Carlos, California
Glycomine Inc. Questions
Glycomine Inc.'s helpline number is (415)617-5755
Glycomine Inc.'s website is glycomine.com
Glycomine Inc.'s LinkedIn profile is https://www.linkedin.com/company/glycomine-inc-
Glycomine Inc. has
23 employees.
View email and phone details for 23
employees at Glycomine Inc..
Glycomine Inc.'s industry is
Biotechnology Research
Glycomine Inc.'s top competitors are
Swing Therapeutics, Inc.,
Marin Biologic Laboratories,
Nuvig Therapeutics Inc.,
Wonderfeel Biosciences,
Tierra Biosciences,
Panacro,
Cellmax Life,
Marea Therapeutics,
Karyon Bio,
Gate Bioscience.
Glycomine Inc.'s support email address is info@glycomine.com
Glycomine Inc.'s categories are Biotechnology Research
